Annual EBITDA
$399.76 M
+$249.33 M+165.75%
31 December 2023
Summary:
Amneal Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently $399.76 million, with the most recent change of +$249.33 million (+165.75%) on 31 December 2023. During the last 3 years, it has risen by +$54.15 million (+15.67%). AMRX annual EBITDA is now -0.33% below its all-time high of $401.10 million, reached on 31 December 2021.AMRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$139.90 M
-$1.80 M-1.27%
30 September 2024
Summary:
Amneal Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently $139.90 million, with the most recent change of -$1.80 million (-1.27%) on 30 September 2024. Over the past year, it has increased by +$8.82 million (+6.73%). AMRX quarterly EBITDA is now -1.27% below its all-time high of $141.70 million, reached on 30 June 2024.AMRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$360.32 M
+$8.82 M+2.51%
30 September 2024
Summary:
Amneal Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $360.32 million, with the most recent change of +$8.82 million (+2.51%) on 30 September 2024. Over the past year, it has dropped by -$106.85 million (-22.87%). AMRX TTM EBITDA is now -22.87% below its all-time high of $467.17 million, reached on 30 September 2023.AMRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AMRX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +165.8% | +6.7% | -22.9% |
| 3 y3 years | +15.7% | +51.2% | -12.4% |
| 5 y5 years | +410.9% | +14.8% | +85.0% |
AMRX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -0.3% | +165.8% | -1.3% | +201.8% | -22.9% | +212.8% |
| 5 y | 5 years | -0.3% | +410.9% | -1.3% | +201.8% | -22.9% | +212.8% |
| alltime | all time | -0.3% | +410.9% | -1.3% | +172.2% | -22.9% | +812.1% |
Amneal Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $139.90 M(-1.3%) | $360.32 M(+2.5%) |
| June 2024 | - | $141.70 M(+210.0%) | $351.50 M(+1.2%) |
| Mar 2024 | - | $45.71 M(+38.4%) | $347.43 M(-13.1%) |
| Dec 2023 | $399.76 M(+165.8%) | $33.02 M(-74.8%) | $399.76 M(-14.4%) |
| Sept 2023 | - | $131.07 M(-4.8%) | $467.17 M(+5.6%) |
| June 2023 | - | $137.63 M(+40.4%) | $442.27 M(+164.5%) |
| Mar 2023 | - | $98.04 M(-2.4%) | $167.24 M(+11.2%) |
| Dec 2022 | $150.43 M(-62.5%) | $100.43 M(-5.4%) | $150.43 M(+16.8%) |
| Sept 2022 | - | $106.18 M(-177.3%) | $128.82 M(+11.8%) |
| June 2022 | - | -$137.41 M(-269.2%) | $115.18 M(-69.5%) |
| Mar 2022 | - | $81.23 M(+3.1%) | $377.99 M(-5.8%) |
| Dec 2021 | $401.10 M(+16.1%) | $78.82 M(-14.8%) | $401.10 M(-2.5%) |
| Sept 2021 | - | $92.54 M(-26.2%) | $411.21 M(+5.2%) |
| June 2021 | - | $125.39 M(+20.2%) | $391.03 M(+15.5%) |
| Mar 2021 | - | $104.34 M(+17.3%) | $338.62 M(-2.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $345.61 M(+122.7%) | $88.93 M(+22.9%) | $345.61 M(+18.1%) |
| Sept 2020 | - | $72.36 M(-0.8%) | $292.69 M(-14.5%) |
| June 2020 | - | $72.98 M(-34.4%) | $342.17 M(+11.3%) |
| Mar 2020 | - | $111.33 M(+209.1%) | $307.56 M(+98.2%) |
| Dec 2019 | $155.20 M(+98.3%) | $36.02 M(-70.4%) | $155.20 M(-20.3%) |
| Sept 2019 | - | $121.84 M(+217.6%) | $194.74 M(+7.3%) |
| June 2019 | - | $38.37 M(-193.5%) | $181.51 M(-458.7%) |
| Mar 2019 | - | -$41.03 M(-154.3%) | -$50.60 M(-164.7%) |
| Dec 2018 | $78.25 M(-72.9%) | $75.57 M(-30.4%) | $78.25 M(-19.8%) |
| Sept 2018 | - | $108.61 M(-156.1%) | $97.56 M(+109.7%) |
| June 2018 | - | -$193.74 M(-320.6%) | $46.51 M(-84.4%) |
| Mar 2018 | - | $87.82 M(-7.4%) | $297.58 M(+41.9%) |
| Dec 2017 | $288.32 M(-4.9%) | $94.87 M(+64.8%) | $209.76 M(+82.6%) |
| Sept 2017 | - | $57.56 M(+0.4%) | $114.89 M(+100.4%) |
| June 2017 | - | $57.33 M | $57.33 M |
| Dec 2016 | $303.12 M | - | - |
FAQ
- What is Amneal Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals annual EBITDA year-on-year change?
- What is Amneal Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Amneal Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals TTM EBITDA year-on-year change?
What is Amneal Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of AMRX is $399.76 M
What is the all time high annual EBITDA for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $401.10 M
What is Amneal Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, AMRX annual earnings before interest, taxes, depreciation & amortization has changed by +$249.33 M (+165.75%)
What is Amneal Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of AMRX is $139.90 M
What is the all time high quarterly EBITDA for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $141.70 M
What is Amneal Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, AMRX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$8.82 M (+6.73%)
What is Amneal Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of AMRX is $360.32 M
What is the all time high TTM EBITDA for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $467.17 M
What is Amneal Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, AMRX TTM earnings before interest, taxes, depreciation & amortization has changed by -$106.85 M (-22.87%)